These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4025155)

  • 21. Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure.
    Klein NA; Siskind SJ; Frishman WH; Sonnenblick EH; LeJemtel TH
    Am J Cardiol; 1981 Jul; 48(1):170-5. PubMed ID: 7246440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents.
    Tisdale JE; Patel R; Webb CR; Borzak S; Zarowitz BJ
    Prog Cardiovasc Dis; 1995; 38(2):167-80. PubMed ID: 7568905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure.
    Robinson PJ; Lvoff R; Chong B; Barrett PA
    Aust N Z J Med; 1981 Dec; 11(6):666-8. PubMed ID: 6949545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
    Bayliss J; Norell M; Canepa-Anson R; Reuben SR; Poole-Wilson PA; Sutton GC
    Br Heart J; 1983 Mar; 49(3):214-21. PubMed ID: 6830658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of amrinone on myocardial energetics in severe congestive heart failure.
    Baim DS
    Am J Cardiol; 1985 Jul; 56(3):16B-18B. PubMed ID: 3161318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro electrophysiologic properties of amrinone in mammalian cardiac tissue.
    Piwonka RW; Canniff PC; Farah AE
    J Cardiovasc Pharmacol; 1983; 5(6):1058-67. PubMed ID: 6196555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Dec; 26(6):468-502. PubMed ID: 6360634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with amrinone in patients with advanced congestive heart failure.
    Kinney EL; Carlin B; Ballard JO; Burks JM; Hallahan WF; Zelis R
    J Clin Pharmacol; 1982 Oct; 22(10):433-40. PubMed ID: 7174853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrophysiological actions of amrinone in dogs with cardiac lesions.
    Piwonka RW; Healey JF; Canniff PC; Farah AE
    J Cardiovasc Pharmacol; 1983; 5(6):1052-7. PubMed ID: 6196554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
    Massie B; Bourassa M; DiBianco R; Hess M; Konstam M; Likoff M; Packer M
    Circulation; 1985 May; 71(5):963-71. PubMed ID: 3886191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical safety of intravenous amrinone--a review.
    Treadway G
    Am J Cardiol; 1985 Jul; 56(3):39B-40B. PubMed ID: 3895878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure.
    Siegel LA; Keung E; Siskind SJ; Forman R; Feinberg H; Strom J; Efstathakis D; Sonnenblick EH; LeJemtel TH
    Circulation; 1981 Apr; 63(4):838-44. PubMed ID: 7471340
    [No Abstract]   [Full Text] [Related]  

  • 33. Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone.
    Guimond JG; Matuschak GM; Meyers F; Keating D
    Chest; 1986 Aug; 90(2):302-4. PubMed ID: 3731911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study.
    Evans JR; Pacht K; Huss P; Unverferth DV; Bashore TM; Leier CV
    Int J Clin Pharmacol Res; 1984; 4(1):9-18. PubMed ID: 6381344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol.
    Firth BG; Ratner AV; Grassman ED; Winniford MD; Nicod P; Hillis LD
    Am J Cardiol; 1984 Dec; 54(10):1331-6. PubMed ID: 6507308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Amrinone in acute and long-term therapy].
    Klepzig M; Kleinhans E; Büll U; Strauer BE
    Z Kardiol; 1985 Feb; 74(2):85-90. PubMed ID: 3922139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemodynamic dose-response effects of intravenous amrinone in left ventricular failure complicating acute myocardial infarction.
    Verma SP; Silke B; Reynolds GW; Hafizullah M; Jackson NC; Taylor SH
    J Cardiovasc Pharmacol; 1985; 7(6):1101-6. PubMed ID: 2418295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease.
    Maskin CS; Forman R; Klein NA; Sonnenblick EH; LeJemtel TH
    Am J Med; 1982 Jan; 72(1):113-8. PubMed ID: 7058816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
    Bassett AL; Gaide MS; Lodge NJ; Cameron JS
    Adv Myocardiol; 1985; 6():629-36. PubMed ID: 2986264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of amrinone administered orally and by injection in heart failure].
    Bounhoure JP; Massabuau P; Puel J; Miquel JP; Calazel J
    Ann Med Interne (Paris); 1985; 136(3):251-5. PubMed ID: 3896092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.